FOLD Stock Analysis: Buy, Sell, or Hold?
FOLD - Amicus Therapeutics, Inc
$14.29
0.02 (0.14%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 18, 2026
17d
Get Alerted When FOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FOLD is fairly valued with market pricing in 4.4% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: FOLD is fairly valued with market pricing in 4.4% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.46
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$15.19
5.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FOLD is currently trading at $14.29, which is considered fair relative to its 30-day fair value range of $14.24 to $14.32. From a valuation perspective, the stock is trading at a premium (Forward PE: 22.0) compared to its historical average (19.4). At these levels, the market is pricing in 4.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FOLD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FOLD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$14.24 -
$14.32
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.2%
Protect Your Profits
FOLD is technically overbought (RSI 80). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($14.50)
- NEUTRAL: Market pricing in 4.4% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$14.24 -
$14.32
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$14.27
Resistance Level
$14.36
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
22.04
Wall Street Target
$14.50
(+1.6%)
Revenue Growth (YoY)
19.5%
Profit Margin
-2.4%
Valuation Premium vs History
+4.4% premium
PE vs Historical
22.0 vs 19.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.4%
(market-implied from PE analysis)
1-Year Target
$14.90
(+4%)
2-Year Target
$15.55
(+9%)
3-Year Target
$16.24
(+14%)
3-Yr Target (if PE normalizes)
(PE: 22→19)
PE COMPRESSION
$14.29
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 71.1%)
$48.72
(+242%)
Base:
(SPY PE: 22.0, Growth: 71.1%)
$48.16
(+238%)
Bear:
(PE: 18.7, Growth: 71.1%)
$40.94
(+187%)
Last updated: January 31, 2026 12:38 AM ET
Data refreshes hourly during market hours. Next update: 1:38 AM
Data refreshes hourly during market hours. Next update: 1:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$486 | 45 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$214 | 60 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$273 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$19 | 55 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$31 | 55 HOLD |
Advanced FOLD Option Strategies
Professional options setups generated by AI based on today's FOLD price and gamma walls.
